Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Treosulfan SCHEMBL5399430 | 1.00 | USP2 (0.43) | USP2ALDH1A1TSHRKDM4ELMNA | |
| Treosulfan SCHEMBL8466701 | 1.00 | USP2 (0.43) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL9359843 | 0.91 | LMNA (0.37) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL9359906 | 0.91 | LMNA (0.37) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL4951404 | 0.90 | ALDH1A1 (0.40) | USP2ALDH1A1TSHRKDM4ELMNA | |
| Treosulfan SCHEMBL28276683 | 0.89 | KDM4E (0.36) | USP2ALDH1A1TSHRKDM4ELMNA | |
| Treosulfan SCHEMBL28142583 | 0.89 | KDM4E (0.36) | USP2ALDH1A1TSHRKDM4ELMNA | |
| Treosulfan SCHEMBL28086148 | 0.89 | TSHR (0.65) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL7621803 | 0.87 | CA1 (0.39) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL21815666 | 0.87 | ALDH1A1 (0.39) | USP2ALDH1A1TSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18018 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260102475-A1 | REGIMEN FOR ENZYMATIC DESENSITISATION | Hansa Biopharma AB (SE) | 2026-04-16 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260091119-A1 | ISOLATED TARGETED DELIVERY SYSTEM FOR THE TREATMENT OF GLIOMA | CELLIS AG (CH) | 2026-04-02 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4257122-B1 | LYOPHILISATE OF TREOSULFAN | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20260028400-A1 | ANTI-ROR1 ANTIBODY AND USE THEREOF | AIMED BIO INC (KR) | 2026-01-29 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | claimed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| WO-2001032154-A2 | USE OF TREOSULFAN FOR PATIENT CONDITIONING BEFORE BONE MARROW OR BLOOD STEM CELL TRANSPLANTATION | Medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2001-05-10 | — | — | WO | claimed |
| WO-2000045842-A2 | METHODS FOR HUMAN ALLOGRAFTING | THE GENERAL HOSPITAL CORPORATION (US) | 2000-08-10 | — | — | WO | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-2000020022-A1 | METHODS FOR THE TREATMENT OF CANCER USING CYTOKINES IN COMBINATION WITH LOW LEVEL DOSES OF CHEMOTHERAPY AND/OR RADIOTHERAPY | LT TECHNOLOGY COMPANY, LLC. (US) | 2000-04-13 | — | — | WO | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |